SAM, Linklaters, JSA Act On Biocon’s $460 Million QIP Biopharamaceuticals January 19, 2026 Capital Markets
SAM Advised On Biocon Biologics Merger; Khaitan, Cravath Act On Viatris’ Stake Sale In Biologics Biopharamaceuticals December 9, 2025 Mergers & Acquisitions
Paul, Weiss & Wachtell Advised On Pfizer’s Acquisition Of Metsera Biopharamaceuticals September 29, 2025 Mergers & Acquisitions
Gibson Dunn & Sidley Austin Advise On Roche’s $3.5 Billion Acquisition of 89bio, Inc. Biopharamaceuticals September 22, 2025 Mergers & Acquisitions
JSA Advised Biocon Limited In Raising ₹4500 Cr Through A QIP Biopharamaceuticals June 27, 2025 Capital Markets – Equity
